The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier

Table 2

Tyrosine hydroxylase (TH) in brain and peripheral organs in the rat 3 days after intravenous injection of gene therapy with TH expression plasmids driven by either the SV40 promoter (clone 877) or the Gfap promoter (clone 951), respectively.

Organs	Saline (pmol/hr/mgp)	TfRMAb-THL/877 (pmol/hr/mgp)	TfRMAb-THL/951 (pmol/hr/mgp)
Ipsilateral striatum	128 ± 27	5177 ± 446*	5536 ± 395*
Contralateral striatum	6445 ± 523	5832 ± 391	5713 ± 577
Ipsilateral cortex	176 ± 30	132 ± 16	184 ± 38
Contralateral cortex	150 ± 36	150 ± 24	135 ± 25
Heart	29 ± 3	45 ± 8	31 ± 3
Liver	13 ± 2	130 ± 28**	18 ± 6
Lung	42 ± 13	74 ± 22	30 ± 6
Kidney	24 ± 2	35 ± 5	31 ± 8

* 𝑃<0.01 difference from saline group (ANOVA with Bonferroni correction; 𝑛=4 rats per group). Rats were lesioned with intracerebral injections of 6-hydroxydopamine; 3 weeks after toxin injection, the rats were tested for apomorphine-induced rotation behavior; those rats testing positively to apomorphine were selected for gene therapy, which was administered intravenously 4 weeks after toxin administration; all animals were euthanized 3 days after gene administration. From [30].